Inarigivir soproxil/tenofovir disoproxil fumarate - Spring Bank Pharmaceuticals

Drug Profile

Inarigivir soproxil/tenofovir disoproxil fumarate - Spring Bank Pharmaceuticals

Alternative Names: Inarigivir soproxil/tenofovir disoproxil fumarate; SB 11399; SB 9200/tenofovir disoproxil fumarate; SB 9225

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Class Antiretrovirals; Antivirals; Nucleotides; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action DDX58 protein stimulants; NOD2 protein antagonists; Nucleotide reverse transcriptase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Hepatitis B

Most Recent Events

  • 28 Mar 2018 Chemical structure information added
  • 20 Feb 2018 Spring Bank Pharmaceuticals plans a phase III trial for Hepatitis B in USA in 2019 (CTP#294220)
  • 12 Oct 2017 Clinical trials in Hepatitis B in USA (PO) before October 2017 (Spring Bank Pharmaceuticals pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top